Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study
Kansas City Heart Rhythm Research Foundation
400 participants
Feb 12, 2024
OBSERVATIONAL
Conditions
Summary
Observational two phase, retrospective and prospective registry study to assess the prevalence of and characterize outcomes of autonomic dysfunction (AD) in patients who undergo bariatric surgery (BS) and to better define the underlying pathophysiology of AD following BS.
Eligibility
Inclusion Criteria7
- Between the age of 18 - 85 years
- Can provide consent
- Negative urine B-hCG
- Continued follow-up with the bariatric surgery team.
- BS includes one of the following: gastric bypass, sleeve gastrectomy, and biliopancreatic diversion with duodenal switch.
- Phase I: Underwent BS within the last 3 years
- Phase II: Will undergo BS within the next 3 months or underwent BS in the last 30 days
Exclusion Criteria7
- Unable to provide consent
- Pregnant or breastfeeding
- BMI < 35
- Revision surgery of one of the following BS from above
- Prior history of autonomic dysfunction prior to BS
- Developed AD 72 months post-procedure
- No evidence of AD/OI
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation. Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06289413